银屑病的免疫生物学疗法

Biological therapy of psoriasis

银屑病是一种慢性T细胞介导的炎性和增殖性皮肤病,近年来有关银屑病的治疗一直是个令人困惑的问题。随着银屑病免疫病理机制研究的不断深入及基因工程技术的突飞猛进,已研制或正在研制一批生物制剂,包括融合蛋白、单克隆抗体、重组细胞因子等。这些生物制剂具有靶向特异性、疗效确切、毒副作用少,为中、重度银屑病治疗提供了新的方向。现就近年来银屑病的生物学疗法及其进展进行综述。

Psoriasis is a chronic T-lymphocyte mediated inflammatory and proliferous skin disease, and its treatment is still a puzzled problem. With the study of immune pathogenesis and the progress of genetic engineering technology, several novel engineered proteins （biological agents ）designed to block specific steps in immune activation have demonstrated efficacy in the treatment of psoriasis. These agents include fusion proteins, monoclonal antibodies and recombinant cytokines etc. The potential increased selectivity for specific pathways in immune activation, clinical efficacy and relative safety of these new agents offer an alternative for the treatment of moderate to severe psoriasis,